Teva Exits Cancer Drug IP Row With 2031 Generic License
The maker of blockbuster cancer treatment Cabometyx has dropped patent litigation against Teva Pharmaceuticals over a planned generic, instead striking a licensing deal that permits an off-brand version of the drug...To view the full article, register now.
Already a subscriber? Click here to view full article